WHO Approves India’s Covaxin for Emergency Use

The World Health Organization (WHO) has granted approval for emergency use to India’s homegrown COVID-19 vaccine Covaxin on Nov. 3.

Developed by Bharat Biotech, Covaxin becomes the eight COVID-19 vaccine to be added to WHO’s emergency use listing.

The approval came after WHO’s Technical Advisory Group determined that the vaccine met its standards and that its benefits outweighed the risks.

WHO said that the vaccine had 78% efficacy against COVID-19 of any severity, 14 or more days after the second dose.

WHO’s vaccines advisory panel recommended the use of the vaccine in two doses with an interval of four weeks for people aged 18 and above.

WHO added that the Covaxin was “extremely suitable” for low- and middle-income countries due to its easy storage requirements.

“Validation by WHO is a very significant step towards ensuring global access to India’s widely administered, safe, and efficacious Covaxin,” Bharat Biotech Chairman and Managing Director Krishna Ella said in a statement.

Ella added that the emergency use authorization “will enable us to contribute to accelerating the equitable access of COVID-19 vaccine, and the access to our vaccine globally thereby addressing the current public health emergency.”


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.